# Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers

> **NCT03431272** · PHASE4 · WITHDRAWN · sponsor: **University of Alabama at Birmingham**

## Conditions studied

- Contact Lens Dry Eye

## Interventions

- **DRUG:** Lifitegrast

## Key facts

- **NCT ID:** NCT03431272
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-11-01
- **Primary completion:** 2018-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** no longer interest / resources to start study
- **Last updated:** 2018-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03431272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03431272, "Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03431272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*